Open an account

Aeolus Pharmaceuticals

AOLS · OTC

$0.00−$0.0001 (−99.00%)TodayMarket open · · Delayed 15 min
No price history for this range.

About AOLS

Aeolus Pharmaceuticals, Inc. is a pharmaceutical company, which engages in developing a portfolio of novel metalloporphyrins. AEOL-10150 is catalytic antioxidant compound based on technology developed at Duke University and National Jewish Health. These compounds, known as metalloporphyrins, scavenge reactive oxygen species at the cellular level, mimicking the effect of the body’s own natural antioxidant enzyme superoxide dismutase. The Company’s products include AEOL 10150, AEOL 11207, and ED-Customer.com. The company also has two programs underway for the development of its second drug candidate, AEOL 11207, for the treatment of epilepsy and Parkinson’s disease. Its AEOL 10150 product includes catalytic antioxidant program, which is designed to retain the catalytic mechanism and high antioxidant efficiency of the natural enzymes and create and develop stable and small molecule antioxidants without the limitations of superoxide dismutase.

Employees
4
Headquarters
Mission Viejo, California
Listed
Feb 2, 1996
Sector
Health Care
Industry
Pharmaceuticals
Website
aeoluspharma.com

AOLS key statistics

Market cap
152
Price-earnings ratio
-0.00
Dividend yield
—
Average volume
38.92K
Volume
312.99K
Open price
$0.0001
High today
$0.0001
Low today
$0.00
52 Week high
$0.0001
52 Week low
$0.00

Aeolus Pharmaceuticals (AOLS) at a glance

Aeolus Pharmaceuticals (AOLS) last traded at $0.00, with a market cap of 152 and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.00 and $0.0001. The current price is 0.0% above the day's low and 99.0% below its high.

Volume so far is 312.99K shares, above the average of 38.92K shares a day.

Over the past year Aeolus Pharmaceuticals has ranged from $0.00 to $0.0001, and now sits 0% of the way up that range.

Aeolus Pharmaceuticals met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q3 FY15 it reported -$0.01 per share against an estimate of $0.00.

AOLS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 1 of the last 8 quarters, by 100.0% on average.

  1. Q4 FY13: reported $0.00 per share against an estimate of $0.00
  2. Q1 FY14: reported -$0.01 per share against an estimate of $0.00
  3. Q2 FY14: reported $0.00 per share against an estimate of -$0.0102
  4. Q3 FY14: reported $0.01 per share against an estimate of $0.0102
  5. Q4 FY14: reported $0.00 per share against an estimate of $0.00
  6. Q1 FY15: reported -$0.01 per share against an estimate of $0.00
  7. Q2 FY15: reported -$0.01 per share against an estimate of $0.00
  8. Q3 FY15: reported -$0.01 per share against an estimate of $0.00

Similar companies

Companies in the same industry as Aeolus Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.